Anjali T Sibley, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sibley’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C143846 · Current
Licensed to practise in California · since 2016 · expires 2027-10-31 · University of Tennessee College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Tennessee 47748Medical Doctor · since 2011 · expires 2017-10-31Specialty on the licence: HematologyExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
4 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Education
- University of Tennessee · MDMEMPHIS, TN · 2003Medical school
Residency and fellowship
- University of ArkansasLITTLE ROCK, AR · 2007–2010
- Mt. Auburn HospitalCAMBRIDGE, MA · 2005–2007
- Mt. Auburn HospitalCAMBRIDGE, MA · 2004–2005
- Baylor InstituteDALLAS, TX · 2003–2004
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$149,759
Medicare paid this office $149,759 for 382 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 347 | $83,271 | $93 |
| Long return visit (40+ min) | 111 | $53,823 | $141 |
| New patient visit (60+ min) | 44 | $8,063 | $183 |
| New patient visit (45+ min) | 26 | $3,003 | $111 |
| Short return visit (20+ min) | 19 | $1,500 | $71 |
Who their Medicare patients are
382 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 17% · Women 56% · Also on Medicaid 12% · Health risk score 1.79. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 69% · Cancer 37% · Chronic kidney disease 33% · Diabetes 28% · Coronary heart disease 27% · Atrial fibrillation 19% · Depression 19% · Heart failure 17% · COPD 13% · Stroke 10% · Dementia 5%.
The office billed $602,792, Medicare allowed $201,522 and paid $149,759; for 1,376 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 382 | 1,376 | 76 | 1.79 | $602,792 | $149,759 |
| 2023 | 339 | 1,268 | 76 | 1.68 | $461,530 | $119,243 |
| 2022 | 296 | 1,296 | 76 | 1.72 | $382,765 | $85,782 |
| 2021 | 233 | 857 | 74 | 1.50 | $213,805 | $64,921 |
| 2020 | 48 | 608 | 70 | 3.00 | $57,892 | $13,328 |
| 2019 | 21 | 31 | 69 | 3.61 | $30,743 | $7,818 |
| 2015 | 80 | 457 | 70 | 2.11 | $97,553 | $21,267 |
| 2014 | 82 | 459 | 70 | 2.30 | $96,611 | $22,424 |
| 2013 | 97 | 386 | 68 | 2.16 | $83,264 | $20,713 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 298 | $66,379 | $83 |
| Long return visit (40+ min) | 111 | $38,465 | $126 |
| New patient visit (60+ min) | 47 | $7,545 | $161 |
| New patient visit (45+ min) | 35 | $4,088 | $117 |
| Short return visit (20+ min) | 66 | $2,437 | $33 |
2022: 6 services
| Short return visit (20+ min) | 267 | $44,575 | $54 |
| Return visit (30+ min) | 147 | $29,493 | $86 |
| New patient visit (45+ min) | 54 | $4,987 | $92 |
| New patient visit (60+ min) | 23 | $3,801 | $165 |
| New patient visit (30+ min) | 11 | $596 | $54 |
| Short return visit | 14 | $479 | $32 |
2021: 7 services
| Short return visit (20+ min) | 193 | $30,802 | $57 |
| Return visit (30+ min) | 81 | $12,113 | $87 |
| New patient visit (60+ min) | 58 | $9,385 | $162 |
| New patient visit (45+ min) | 79 | $9,376 | $119 |
| Long return visit (40+ min) | 13 | $1,630 | $125 |
| New patient visit (30+ min) | 16 | $1,217 | $76 |
| Short return visit | 11 | $370 | $31 |
2020: 1 service
| Short return visit (20+ min) | 19 | $2,193 | $48 |
2015: 4 services
| Return visit (30+ min) | 34 | $9,344 | $55 |
| Short return visit (20+ min) | 67 | $8,288 | $36 |
| New patient visit (60+ min) | 11 | $1,146 | $104 |
| Short return visit | 13 | $248 | $15 |
2014: 4 services
| Return visit (30+ min) | 43 | $10,436 | $55 |
| Short return visit (20+ min) | 57 | $7,248 | $36 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $890 | $52 |
| Short return visit | 12 | $264 | $19 |
2013: 5 services
| Return visit (30+ min) | 40 | $8,338 | $56 |
| Short return visit (20+ min) | 49 | $4,354 | $35 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,537 | $51 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,531 | $77 |
| New patient visit (60+ min) | 12 | $1,350 | $112 |
Medicaid work
$156,255 in 2020
Medicaid paid $156,255 for 3,612 billed services this clinician did in 2020, up to 66 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 404 | $132,135 |
| Service | 300 | $24,120 |
| Service | 115 | $0 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 187 | $0 |
| COMPREHENSIVE METABOLIC PANEL | 79 | $0 |
| Measurement of vitamin D 25 hydroxy | 14 | $0 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 269 | $0 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 96 | $0 |
| Short return visit | 99 | $0 |
| Short return visit (20+ min) | 264 | $0 |
| Return visit (30+ min) | 56 | $0 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 258 | $0 |
| 2020 | 3,612 | 19 | 66 | $156,255 |
| 2019 | 6,900 | 21 | 77 | $353,764 |
| 2018 | 2,815 | 12 | 52 | $271,659 |
See the largest Medicaid services in earlier years
2019
| Clinic visit/encounter, all-inclusive | 847 | $276,810 |
| Service | 940 | $76,954 |
| Service | 106 | $0 |
| Service | 186 | $0 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 574 | $0 |
| Basic metabolic panel (Calcium, total) This panel must include the following: Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520) | 56 | $0 |
| COMPREHENSIVE METABOLIC PANEL | 259 | $0 |
| HEPATIC FUNCTION PANEL | 82 | $0 |
| VITAMIN B-12 | 16 | $0 |
| Measurement of iron | 16 | $0 |
| Measurement of transferrin | 16 | $0 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 634 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 686 | $222,271 |
| Service | 604 | $49,388 |
| Service | 17 | $0 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 279 | $0 |
| COMPREHENSIVE METABOLIC PANEL | 82 | $0 |
| HEPATIC FUNCTION PANEL | 18 | $0 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 305 | $0 |
| Short return visit (20+ min) | 262 | $0 |
| Return visit (30+ min) | 236 | $0 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 16 | $0 |
| Unclassified drugs | 253 | $0 |
| Infusion, normal saline solution , 1000 cc | 57 | $0 |
Drugs they prescribed that Part D paid
$1,515,791
Pharmacies billed $1,515,791 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (45 of 919) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 27% of their opioid prescriptions.
674 generic and 245 brand-name prescriptions · $1,515,791 in drug cost · 42 antibiotic prescriptions to 31 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 115 | $104,661 | $910 |
| Xarelto | 12 | $20,503 | $1,709 |
| Megestrol Acetate | 25 | $1,988 | $80 |
| Ondansetron | 32 | $1,162 | $36 |
| Albuterol Sulfate Hfa | 20 | $940 | $47 |
See all 23 drugs
| Eliquis | 115 | $104,661 | $910 |
| Xarelto | 12 | $20,503 | $1,709 |
| Megestrol Acetate | 25 | $1,988 | $80 |
| Ondansetron | 32 | $1,162 | $36 |
| Albuterol Sulfate Hfa | 20 | $940 | $47 |
| Exemestane | 24 | $889 | $37 |
| Dexamethasone | 36 | $648 | $18 |
| Anastrozole | 24 | $614 | $26 |
| Letrozole | 17 | $531 | $31 |
| Prochlorperazine Maleate | 26 | $443 | $17 |
| Hydroxyurea | 16 | $342 | $21 |
| Acyclovir | 13 | $319 | $25 |
| Levothyroxine | 17 | $269 | $16 |
| Gabapentin | 15 | $267 | $18 |
| Ondansetron Odt | 11 | $260 | $24 |
| Doxycycline Hyclate | 20 | $201 | $10 |
| Pantoprazole | 11 | $182 | $17 |
| Famotidine | 18 | $165 | $9 |
| Furosemide | 23 | $163 | $7 |
| Folic Acid | 20 | $120 | $6 |
| Prednisone | 16 | $84 | $5 |
| Tramadol | 11 | $35 | $3 |
| Lorazepam | 13 | $33 | $3 |
Year by year
| 2024 | 919 | 210 | 5% (45) | 27% | $1,515,791 |
| 2023 | 896 | 174 | 3% (25) | None | $1,246,059 |
| 2022 | 1,032 | 166 | 5% (50) | None | $955,481 |
| 2021 | 499 | 119 | 5% (26) | None | $440,381 |
| 2020 | 332 | 59 | 14% (47) | None | $217,435 |
| 2019 | 439 | 70 | 19% (81) | 21% | $449,342 |
| 2018 | 333 | 60 | 14% (46) | None | $78,170 |
| 2017 | 422 | 40 | 11% (45) | None | $41,613 |
| 2016 | 72 | 24 | None | None | $4,933 |
| 2015 | 597 | 64 | 15% (92) | None | $360,400 |
| 2014 | 563 | 61 | 22% (125) | None | $144,276 |
| 2013 | 256 | 47 | 32% (83) | None | $16,083 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Ibrance | 11 | $177,144 | $16,104 |
| Brukinsa | 11 | $169,681 | $15,426 |
| Eliquis | 97 | $87,209 | $899 |
| Xarelto | 12 | $21,183 | $1,765 |
| Exemestane | 12 | $2,857 | $238 |
| Megestrol Acetate | 14 | $1,554 | $111 |
| Anastrozole | 31 | $1,044 | $34 |
| Hydroxyurea | 20 | $788 | $39 |
| Ondansetron | 41 | $648 | $16 |
| Dexamethasone | 34 | $536 | $16 |
| Gabapentin | 35 | $514 | $15 |
| Albuterol Sulfate Hfa | 16 | $449 | $28 |
| Levothyroxine | 18 | $403 | $22 |
| Prochlorperazine Maleate | 24 | $328 | $14 |
| Pantoprazole | 15 | $317 | $21 |
| Letrozole | 13 | $309 | $24 |
| Prednisone | 34 | $271 | $8 |
| Fluoxetine | 11 | $168 | $15 |
| Furosemide | 29 | $163 | $6 |
| Doxycycline Hyclate | 16 | $124 | $8 |
| Lorazepam | 14 | $68 | $5 |
2022: 24 drugs
| Eliquis | 94 | $73,719 | $784 |
| Xarelto | 12 | $17,881 | $1,490 |
| Abiraterone Acetate | 16 | $17,813 | $1,113 |
| Creon | 11 | $5,860 | $533 |
| Anastrozole | 55 | $1,923 | $35 |
| Megestrol Acetate | 20 | $1,204 | $60 |
| Ondansetron | 48 | $1,030 | $21 |
| Albuterol Sulfate Hfa | 17 | $944 | $56 |
| Pantoprazole | 17 | $873 | $51 |
| Morphine Sulfate Er | 11 | $601 | $55 |
| Hydroxyurea | 20 | $517 | $26 |
| Gabapentin | 29 | $463 | $16 |
| Letrozole | 19 | $460 | $24 |
| Levothyroxine | 23 | $452 | $20 |
| Prochlorperazine Maleate | 33 | $451 | $14 |
| Prednisone | 49 | $422 | $9 |
| Famotidine | 32 | $333 | $10 |
| Dexamethasone | 19 | $320 | $17 |
| Hydrocodone-Acetaminophen | 12 | $181 | $15 |
| Furosemide | 44 | $155 | $4 |
| Tramadol | 16 | $108 | $7 |
| Omeprazole | 11 | $92 | $8 |
| Olanzapine | 16 | $82 | $5 |
| Lorazepam | 14 | $34 | $2 |
2021: 12 drugs
| Eliquis | 32 | $22,483 | $703 |
| Anastrozole | 25 | $1,221 | $49 |
| Megestrol Acetate | 20 | $806 | $40 |
| Ondansetron | 26 | $640 | $25 |
| Levothyroxine | 16 | $359 | $22 |
| Pantoprazole | 11 | $269 | $24 |
| Gabapentin | 11 | $234 | $21 |
| Famotidine | 14 | $196 | $14 |
| Prochlorperazine Maleate | 12 | $156 | $13 |
| Tramadol | 12 | $48 | $4 |
| Lorazepam | 13 | $35 | $3 |
| Furosemide | 13 | $31 | $2 |
2020: 6 drugs
| Eliquis | 11 | $6,907 | $628 |
| Anastrozole | 21 | $639 | $30 |
| Ondansetron | 21 | $469 | $22 |
| Hydrocodone-Acetaminophen | 20 | $401 | $20 |
| Promethazine | 14 | $88 | $6 |
| Tramadol | 12 | $77 | $6 |
2019: 9 drugs
| Hydrocodone-Acetaminophen | 41 | $908 | $22 |
| Megestrol Acetate | 11 | $804 | $73 |
| Anastrozole | 28 | $478 | $17 |
| Tramadol | 27 | $172 | $6 |
| Dexamethasone | 11 | $171 | $16 |
| Mupirocin | 11 | $152 | $14 |
| Loperamide | 11 | $145 | $13 |
| Prednisone | 12 | $89 | $7 |
| Promethazine | 11 | $71 | $6 |
2018: 6 drugs
| Ondansetron | 37 | $540 | $15 |
| Megestrol Acetate | 11 | $520 | $47 |
| Hydrocodone-Acetaminophen | 23 | $511 | $22 |
| Promethazine | 24 | $172 | $7 |
| Dexamethasone | 12 | $149 | $12 |
| Amlodipine Besylate | 11 | $93 | $8 |
2017: 9 drugs
| Lantus | 14 | $7,224 | $516 |
| Ventolin Hfa | 12 | $963 | $80 |
| Megestrol Acetate | 11 | $543 | $49 |
| Cyclobenzaprine | 11 | $417 | $38 |
| Hydrocodone-Acetaminophen | 28 | $250 | $9 |
| Atorvastatin | 13 | $203 | $16 |
| Amlodipine Besylate | 22 | $100 | $5 |
| Omeprazole | 12 | $78 | $6 |
| Hydrochlorothiazide | 12 | $60 | $5 |
2016: 1 drug
| Anastrozole | 11 | $123 | $11 |
2015: 17 drugs
| Enoxaparin | 11 | $21,289 | $1,935 |
| Morphine Sulfate Er | 12 | $1,498 | $125 |
| Oxycodone | 40 | $1,002 | $25 |
| Ondansetron | 35 | $783 | $22 |
| Lidocaine-Prilocaine | 20 | $690 | $35 |
| Megestrol Acetate | 13 | $393 | $30 |
| Gabapentin | 18 | $315 | $17 |
| Levothyroxine | 14 | $299 | $21 |
| Anastrozole | 17 | $261 | $15 |
| Zolpidem | 14 | $194 | $14 |
| Dexamethasone | 27 | $156 | $6 |
| Levofloxacin | 20 | $126 | $6 |
| Tramadol | 13 | $84 | $6 |
| Dicyclomine | 15 | $68 | $5 |
| Alprazolam | 24 | $66 | $3 |
| Triamterene-Hydrochlorothiazid | 12 | $58 | $5 |
| Furosemide | 15 | $20 | $1 |
2014: 13 drugs
| Dronabinol | 14 | $3,736 | $267 |
| Oxycodone | 54 | $1,469 | $27 |
| Ondansetron | 28 | $590 | $21 |
| Levofloxacin | 16 | $364 | $23 |
| Lidocaine-Prilocaine | 13 | $359 | $28 |
| Dexamethasone | 53 | $281 | $5 |
| Sucralfate | 13 | $254 | $20 |
| Pantoprazole | 21 | $245 | $12 |
| Tramadol | 30 | $172 | $6 |
| Morphine Sulfate | 11 | $152 | $14 |
| Promethazine | 13 | $110 | $8 |
| Zolpidem | 12 | $47 | $4 |
| Alprazolam | 15 | $39 | $3 |
2013: 6 drugs
| Morphine Sulfate Er | 12 | $1,070 | $89 |
| Morphine Sulfate | 19 | $404 | $21 |
| Ondansetron | 18 | $396 | $22 |
| Oxycodone | 15 | $229 | $15 |
| Tramadol | 22 | $153 | $7 |
| Dexamethasone | 16 | $114 | $7 |
Money from drug and device companies
$487 in 2025
| 2025 | 13 | 19 | None | $487 |
| 2024 | 8 | 9 | None | $234 |
| 2023 | 7 | 10 | None | $230 |
| 2022 | 4 | 6 | None | $146 |
| 2021 | 2 | 6 | None | $167 |
| 2020 | 4 | 4 | None | $92 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Celgene | Reblozyl | $150 | 5 payments
|
| Array Biopharma | Lorbrena | $59 | 2 payments
|
| Astellas Pharma US | Vyloy | $37 | 2 payments
|
| Janssen Biotech | Rybrevant | $34 | 1 payment
|
| Pfizer | Bosulif | $29 | 1 payment
|
| Kyowa Kirin | Poteligeo | $27 | 1 payment
|
See all 19 published payments
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-06 | Iclusig | $25 |
| Astellas Pharma US | Meals · 2025-10-31 | Vyloy | $19 |
| Celgene | Meals · 2025-10-24 | Reblozyl | $28 |
| Celgene | Meals · 2025-08-19 | Reblozyl | $31 |
| Array Biopharma | Meals · 2025-08-15 | Braftovi | $26 |
| Gilead Sciences | Meals · 2025-07-30 | Trodelvy | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-15 | Opdivo | $21 |
| Celgene | Meals · 2025-06-25 | Reblozyl | $30 |
| Array Biopharma | Meals · 2025-06-13 | Lorbrena | $33 |
| GlaxoSmithKline | Meals · 2025-06-04 | Ojjaara | $20 |
| Janssen Biotech | Meals · 2025-05-21 | Rybrevant | $34 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-04-21 | None | $23 |
| SpringWorks Therapeutics | Meals · 2025-04-15 | Ogsiveo | $20 |
| Celgene | Meals · 2025-04-04 | Opdivo | $35 |
| Astellas Pharma US | Meals · 2025-03-28 | Vyloy | $18 |
| Celgene | Meals · 2025-03-11 | Reblozyl | $26 |
| Eisai | Meals · 2025-02-19 | Lenvima | $21 |
| Kyowa Kirin | Meals · 2025-01-29 | Poteligeo | $27 |
| Pfizer | Meals · 2025-01-13 | Bosulif | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $234
| Abbvie | Imbruvica | $45 | 2 payments
|
| GlaxoSmithKline | Jemperli | $32 | 1 payment
|
| Celgene | Reblozyl | $31 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $27 | 1 payment
|
| Eisai | Lenvima | $27 | 1 payment
|
| Array Biopharma | Xalkori | $26 | 1 payment
|
| Novartis Pharmaceuticals | Fabhalta | $25 | 1 payment
|
| SpringWorks Therapeutics | Ogsiveo | $21 | 1 payment
|
2023: $230
| Pfizer | Xtandi | $56 | 3 payments
|
| Celgene | Reblozyl | $54 | 2 payments
|
| Jazz Pharmaceuticals | Zepzelca | $26 | 1 payment
|
| Janssen Biotech | Imbruvica | $25 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $24 | 1 payment
|
| Eisai | Lenvima | $23 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $22 | 1 payment
|
2022: $146
| Daiichi Sankyo | Injectafer | $50 | 2 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $48 | 2 payments
|
| Janssen Biotech | Imbruvica | $24 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $23 | 1 payment
|
2021: $167
| Lilly USA | None | $96 | 1 payment
|
| Pfizer | Lorbrena | $71 | 5 payments
|
2020: $92
| Intuitive Surgical | Da Vinci Surgical System | $36 | 1 payment
|
| Janssen Biotech | Darzalex | $25 | 1 payment
|
| Seagen | Padcev | $18 | 1 payment
|
| Pfizer | Inlyta | $13 | 1 payment
|
Professional record
- NPI
- 1750580080
- Licence
- CA C143846, NH 15046, TN MD47748California C143846: Current · expires 2027-10-31Tennessee 47748: Expired
- Trained
- University of Tennessee, Hsc, College of Medicine, 2003
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-07-17
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5800 Hollis St, Emeryville, CA, 94608